# Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

> **NCT00115791** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 276 (actual)

## Conditions studied

- Atrial Flutter
- Atrial Fibrillation

## Interventions

- **DRUG:** RSD1235
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00115791
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2008-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115791, "Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00115791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*